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Soluble immune checkpoint-related
proteins as predictors of tumor recurrence,
survival, and T cell phenotypes in clear cell
renal cell carcinoma patients
Qinchuan Wang1,2†, Jinhua Zhang2,3†, Huakang Tu2, Dong Liang4, David. W. Chang2, Yuanqing Ye2,5 and
Xifeng Wu2,5*

Abstract
Background: Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. With
the exception of a few candidate biomarkers, the prognostic role of soluble immune checkpoint-related proteins in
clear cell renal cell cancer (ccRCC) patients is largely uninvestigated.
Methods: We profiled the circulating levels of 14 immune checkpoint-related proteins panel (BTLA, GITR, HVEM,
IDO, LAG-3, PD-1, PD-L1, PD-L2, Tim-3, CD28, CD80, CD137, CD27 and CTLA-4) and their associations with the risk of
recurrence and death in 182 ccRCC patients using a multiplex Luminex assay. Gene expression in tumors from a
subset of participating patients (n = 47) and another 533 primary ccRCC from TCGA were analyzed to elucidate
potential mechanisms. Our primary endpoint is overall survival; secondary endpoint is recurrence-free survival.
Multivariate Cox proportional hazard model, unconditional logistic regression model, and Kaplan-Meier analysis
were applied in the study.
Results: sTIM3 and sLAG3 were significantly associated with advanced (stage III) disease (P < 0.05). sPD-L2 was the
strongest predictor of recurrence (HR 2.51, 95%CI 1.46–4.34, P = 9.33E-04), whereas high sBTLA and sTIM3 was
associated with decreased survival (HR 6.02, 95%CI 2.0–18.1, P = 1.39E-03 and HR 3.12, 95%CI 1.44–6.75, P = 3.94E-03,
respectively). Risk scores based on sTIM3 and sBTLA indicated that the soluble immune checkpoint-related proteins
jointly predicted recurrence and death risks of ccRCC (P = 0.01 and 4.44E-04, respectively). Moreover, sLAG3 and
sCD28 were found negatively correlated with cytolytic activity of T cells in tumors (rho = −0.31 and − 0.33, respectively).
Conclusions: Our study provides evidence that soluble immune checkpoint-related proteins may associate with
advanced disease, recurrence and survival in ccRCC patients, which highlights the prognostic values of soluble immune
checkpoint-related proteins. Future independent validation in prospective studies is warranted.
Keywords: Soluble immune checkpoint-related proteins, Clear cell renal cell cancer, Predictor, Survival, Recurrence,
Cytolytic activity
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Introduction
Immunotherapy by immune checkpoint inhibition has
achieved critical success in treating advanced clear cell
renal cell carcinoma (ccRCC) during the past 5 years [1];
however, not all patients benefited from treatment. Although investigations of immune checkpoint genes and
their products in RCC tumors have been conducted in
the past, the prognostic role of soluble immune checkpoint markers has not been extensively explored, especially among localized cancer patients.
Previous studies have implicated high expression of
inhibitory immune checkpoint genes in T cells strongly
linked to T cell exhaustion and inefficient control of
infections and tumors [2]. Giraldo et al. reported that in a
group of 40 localized ccRCC cases the presence of
CD8+PD-1+TIM3+LAG3+ tumor infiltrative lymphocytes
(TILs) with CD4+ICOS+ T-reg cells identified patients
with deleterious prognosis [3]. In a study involving 135
primary ccRCC cases and 51 metastatic ccRCC cases, PDL2 expression in tumor cells and LAG3 expression in TILs
were identified as poor prognostic factors in ccRCC patients [4]. In another cohort of RCC patients from Japan,
high expression of immune checkpoint molecules in TILs
correlated with poor overall and recurrence-free survival
[5]. Thus, the expression of immune checkpoint genes in
both immune and tumor cells may correlate with antitumor immunity in the tumor microenvironment (TME),
pointing to the markers’ prognostic or therapeutic potential in ccRCC.
Only a few studies have examined the association between soluble immune checkpoint-related proteins and
cancer outcomes. Circulating T cell regulatory proteins,
some of which might modulate immune checkpoints,
could be released from immune and tumor cells [6]. High
level of circulating PD-L1 was associated with impaired
immunity and poor outcomes in aggressive RCC, diffused
large B-cell lymphoma and pancreatic cancer [7–9]. A
spliced variant of PD-L1 was also reported to be secreted
in the blood and to induce immune suppression in multiple cancers [10]. He Y et al. reported that low sLAG3
was associated with advanced stage in non-small-cell lung
cancer (NSCLC) [11]. Taken together, these results suggest soluble immune checkpoint-related molecules may
play a prognostic role in RCC and other cancers.
To identify soluble immune checkpoint-related proteins that can predict outcomes of ccRCC, patients, we
implemented a three-stage strategy. First, we systematically assessed the level of soluble immune checkpointrelated proteins and their association with recurrence
and survival in 182 ccRCC cases from an ongoing casecontrol study at The University of Texas MD Anderson
Cancer Center (MDACC). Second, we evaluated the expression of immune genes in ccRCC tumors from the
MDACC cohort, and we analyzed their association with
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cancer outcomes. Third, we analyzed immune gene expression in an external set of RCC tumor data from The
Cancer Genome Atlas (TCGA). In short, this is an integrated, multi-stage investigation focus on peripheral immune checkpoint-related proteins and further supported
by tumoral data from MDACC and TCGA cohorts.

Materials and methods
Study population and data collection

A schematic design of the study is shown in Additional
file 1: Figure S1. ccRCC patients were drawn from an
ongoing case-control study at MDACC (Houston, TX)
initiated in 2002. The study has been approved by
MDACC Institutional Review Board. Details of the study
have been described previously [12]. In brief, all recruited cases were individuals with newly diagnosed
(within 1 year of diagnosis), histologically confirmed
ccRCC. All participants provided written informed consent before participating in the study. Patients’ clinical
and follow-up data were abstracted from medical records. Epidemiologic data were collected by MDACC
Staff interviewers through an in-person interview. Immediately after interview and consent, a 40 ml blood sample
was collected in up to 5 Vacutainer tubes (Fisher Scientific, Waltham MA; consisting of 2 green top (sodium
heparin), 1 red (no additive), 1 lavender (sodium EDTA),
and 1 gold (gel clot activator)) from each participant and
delivered to the laboratory. At the time of blood collection, all patients were previously untreated by surgery or
chemotherapy. The plasma and peripheral blood monocytes (PBMC) were separated and stored in liquid nitrogen for further research. The tumor samples were snap
frozen after they were taken from surgery and then
stored in liquid nitrogen until processing. We selected
only stages I-III and non-Hispanic white patients to
minimize the effect of poor survival due to end-stage
disease or metastasis and the confounding effect of
population stratification, respectively. The study endpoints were overall survival and recurrence.
In addition, mRNA expression and clinical data (updated
on 2016-01-28) for 533 primary ccRCC tumor samples
with complete follow-up data were retrieved from TCGA
using the Firebrowser portal (www.firebrowser.org).
Detection of soluble immune checkpoint proteins in
plasma

Plasma samples were assayed in duplicates using ProcartaPlex Human Immuno-Oncology Checkpoint Panel (Thermo
Fisher, Waltham, MA) in 96-well plate format to quantify
14 human immune checkpoint markers. Assay was conducted according to protocols provided by the manufacturer
using Luminex 200™ instrument and xPONENT® software
(Luminex Corp, Austin, TX). In brief, 20 ul of plasma was
used for each sample and mixed with ProcartaPlex Panel
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capture antibodies that are covalently bound to the surface
of 6.5 μm microspheres dyed with precise proportions of red
and infrared fluorophores to create unique spectral addresses that can be detected in the Luminex platform. Protein quantification is based on a fluorescently labeled
secondary antibody whose signal intensity is proportional to
the detected analyte concentration. A premixed antigen
standard was serial diluted and applied as standard curve,
and an inter-assay control was also used as positive control.
Water or blank was used as negative control. After washing, fluorescent signals from all samples are detected
in Luminex instrument, and data are analyzed using
manufacturer provided software. All inter-assay and
intra-assay coefficients of variation (CV) were below
15%. The Lower limits of quantification (LLOQ) of
analyte was listed in Additonal file 1: Table S1.
Tissue samples and MRNA extraction

All tissues were snap frozen in liquid nitrogen immediately after excision and stored at − 80 °C until use. Total
RNA was extracted using Trizol Reagent (Thermo
Fisher) according to the manufacturer’s instructions.
Gene expression quantitation

Reverse transcription was performed using High-Capacity
cDNA Reverse Transcription Kit according to manufacturer’s instructions (Thermo Fisher). Expression of genes
HAVCR2, CD28, CD27, CD80, CTLA4, BTLA, IDO1,
PDCD1, CD274, PDCD1LG2, LAG3, TNFRSF9, TNFRSF14,
TNFRSF4, PRF1, GZMA and GAPDH were determined
using TaqMan probes (Applied Biosystems, Waltham, MA)
and Fluidigm 96.96 Dynamic Array (Fluidigm, San Francisco, CA), according to the manufacturer’s instructions.
All probes were list in Additional file 1: Table S2.
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estimated the association between each biomarker and
risk of advanced ccRCC comparing early-stage (stage I
and II) and late-stage (stage III) using the unconditional
logistic regression model with adjustment for potential covariates including age, gender, smoking status, BMI, history of hypertension and diabetes. Risks of recurrence or
death associated with each biomarker were analyzed using
the multivariate Cox proportional hazard model with adjustment for the same covariates as listed above plus treatment, stage, grade and histology. A table listing the effects
of covariates on the significance of association is shown in
Additional file 1: Table S3. For the TCGA dataset with
limited host information, only age, sex, stage and grade
were adjusted for the analysis of death risk. To reduce the
likelihood of false discovery, Bonferroni correction for
multiple testing was also applied to P value of association.
Differences in RFS and OS were assessed using the
Kaplan-Meier survival analysis. Risk score was generated
as a sum of the product of the dichotomized expression
level of each significant marker by the beta coefficient in
the Cox model. The risk score for survival was based on
levels of sBTLA, sTIM3. All patients were dichotomized
with the median value of the risk score into low- and
high-risk groups. Cytolytic activity in tumors was calculated based on the geometric mean value of GZMA and
PRF1 expression [15]. Since GZMB is the most common
granzyme in T cell activity, we also included alternative
cytolytic activity calculation based on geometric mean of
GZMB and PRF1. All statistical tests were two-sided with
a significance cut-off at 0.05. All analyses were conducted
using Stata 14.2 statistical software package (Stata Corp,
College Station, TX).

Results
Patient characteristics

Statistical analysis

Recurrence free survival (RFS) was computed from the
date of pathological diagnosis to the date of first documented local or distant recurrence or last follow-up death,
whichever came first. Overall survival (OS) was defined as
duration from diagnosis to death of any cause or last
follow-up. Follow-up time is censored at the end of study
or patient death, whichever comes first. The loss to
follow-up patient was censored in this study. Levels of all
soluble biomarkers and immune genes were dichotomized
using a logistic regression spline model to generate better
fit for non-linear data [13]. The cutoff point to determine
high- and low-level groups was selected based on the
smallest P value in the spline model. Comparison of host
characteristics between subgroups was carried out using
rank-sum test for continuous variables (age and BMI) and
Pearson χ2 test for categorical variables (all other variables), For smoking history, never/former/current smoker
was defined according to our previous study [14]. We

A total of 182 ccRCC cases were enrolled in this study
including 90 early-stage (I and II) and 92 late-stage
(stage III) patients. The demographic and clinical characteristics are listed in Table 1. There were no significant differences in host characteristics between earlyand late-stage patients except for distribution of tumor
grade and frequency of recurrence and death (P = 1.12E07, 3.51E-16 and 0.04, respectively). Among all subjects,
mean age was 59.0 years. Over two-thirds of the patients
were males, and over half of them were smokers. A total
of 80 patients (44.0%) were in obese status (BMI ≥ 30). A
total of 91 (50%) patients had recurrent disease, while 33
(18.1%) patients had died. The median follow-up time
(MFT) was 66.1 months (range: 1.1–134.1).
Soluble immune checkpoint-related proteins are
associated with advanced disease

The Luminex multiplex assay was performed on all
immune checkpoint-related proteins for early-stage
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Table 1 Host characteristics
ccRCC cases, n (%)
Variables

Early stagea

Late stagea

Age, mean (SD)

58.46 (9.85)

59.57 (8.45)

BMI, mean (SD)

30.70 (6.39)

30.12 (7.07)

Male

67 (74.44)

68 (73.91)

Female

23 (25.56)

24 (26.09)

< =60

44 (48.89)

43 (46.74)

> 60

46 (51.11)

49 (53.26)

Sex

Age

Smoking status
Never

40 (44.44)

43 (46.74)

Former

43 (47.78)

42 (45.65)

Current

7 (7.78)

7 (7.61)

45 (50.00)

57 (61.96)

45 (50.00)

35 (38.04)

Yes

65 (72.22)

68 (73.91)

No

25 (27.78)

24 (26.09)

Yes

19 (21.11)

17 (18.48)

No

71 (78.89)

75 (81.52)

1

1

0 (0.00)

2

43 (47.78)

9 (9.78)

3

37 (41.11)

52 (56.52)

4

8 (8.89)

29 (31.52)

None

1 (1.11)

2 (2.17)

Yes

17 (18.9)

74 (80.4)

No

73 (81.1)

18 (19.6)

BMI
< 30
>= 30
Hypertension

Diabetes

b

Tumor grade

Recurrence

Death
Yes

11 (33.3)

22 (66.7)

No

79 (53.0)

70 (47.0)

Surgery-only

64 (70.33)

76 (83.52)

Surgery-plus-chemotherapy

27 (29.67)

15 (16.48)

Treatment

a

Early stage indicated stage I or II disease; late stage indicated stage III disease.
The staging criteria derived from NCCN guidelines 2019 v.2.0
b
Tumor grade based on Fuhrman criteria

and late-stage patients (Additional file 1: Table S4).
Soluble CD137, HVEM, GITR, PD-1, and CD80 levels
demonstrated minimal variations, thus these markers
were not included in subsequent analyses.

Page 4 of 9

We found that sLAG3 levels was increased in latestage patients. Unconditional logistic regression analysis
indicated that high level of sLAG3 (OR, 3.36, 95%CI
1.55–7.27, P = 0.002) were significantly associated with
increased risk of advanced disease (Table 2).
SOLUBLE IMMUNE CHECKPOINT-RELATED PROTEINS
PREDICT ccRCC RECURRENCE AND OVERALL SURVIVAL
Recurrence

Multivariate Cox proportional hazard analysis showed that
patients with high level of sPD-L2 had significantly increased risk of recurrence (HR, 2.51, 95%CI 1.46–4.34, P =
9.33E-04), compare to low-level patients. Kaplan-Meier
analysis indicated that high sPD-L2 levels were associated
with decreased RFS (log-rank P = 0.02) (Fig. 1a, Table 2).
Overall survival (OS)

Multivariate Cox proportional hazard analysis demonstrated that sTIM3 and sBTLA were significantly associated
with death risk in ccRCC patients. The most significant biomarker is sBTLA, patients with high sBTLA level had 6fold increased death risk compare to patients with low
sBTLA (95%CI 2.00–18.10, P = 1.4E-03). The OS was significantly reduced in high sBTLA patients (log-rank P =
9.81E-08) (Fig. 1b). sTIM3 was also significantly associated
with death risk in ccRCC patients (HR = 3.12, 95%CI 1.44–
6.75, P = 3.94E-03), the OS was significantly decreased in
high sTIM3 patients (log-rank P = 6.29E-05) (Fig. 1c).
ASSOCIATION OF sTIM3 WITH SURVIVAL IS DEPENDENT
ON CLINICAL STAGE

Since sTIM3 was associated with both advanced (stage
III) disease and survival, we investigated whether the association of sTIM3 with survival was dependent on clinical stage. In stratified analysis by early-stage (I and II)
and late-stage (III) patients, we found sTIM3’s association with death risk was only significant in early-stage
patients (HR = 36.1, 95%CI 3.73–350, P = 1.95E-03) but
not in late-stage patients (HR = 1.62, 95%CI 0.60–4.42,
P = 0.34) (Additional file 1: Table S5). Significant interaction was also found between sTIM3’s association with
death risk and clinical stage (P = 0.007).
PREDICTION OF ccRCC SURVIVAL BY RISK SCORE

Based on levels of sTIM3 and sBTLA, a risk score for
death risk was developed for all patients. Patients in the
high-risk group and medium-risk group demonstrated
increased risk of death (HR = 12.88, 95%CI 3.62–45.78,
P = 7.88E-05; HR = 3.29, 95%CI 1.14–9.52, P = 0.028,
respectively) compare to low-risk group patients.
Kaplan-Meier survival analysis indicated that the OS was
reduced in high-risk patients (log-rank P = 5.14E-11)
(Fig. 2a, Additional file 1: Table S6).
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Table 2 Soluble immune checkpoint proteins and association with clinical outcomes of ccRCC patients
Protein names

Advanced disease

High vs lowa

Adjusted OR (95%CI)b

sTIM3

1 (reference)
2.61 (1.07–6.40)

sCD27

sPDL1

0.10

1.44 (0.68–3.03)

2.30 (0.96–5.51)

2.13 (1.06–4.28)

0.54

0.48 (0.19–1.23)

0.34

1.38 (0.32–6.00)

0.06

0.61 (0.30–1.27)

0.03

1.51 (0.89–2.56)

0.13

2.51 (1.46–4.34)

0.02

2.71 (1.13–6.47)

0.02

1.12 (0.51–2.44)

0.78

0.49 (0.06–3.99)

0.51

1 (reference)
0.66

2.21 (0.95–5.15)

0.07

1 (reference)
0.19

6.02 (2.00–18.1)

1.39E-03#

1 (reference)
0.12

1 (reference)
0.25

2.80 (1.17–6.67)

1 (reference)

1 (reference)
0.07

3.94E-03#

1 (reference)

1 (reference)
0.25

3.12 (1.44–6.75)

1 (reference)

1 (reference)
2.13E-03#

P value

1 (reference)

1 (reference)

1 (reference)
0.53 (0.18–1.57)

0.32

1 (reference)

1 (reference)
4.59 (0.91–23.3)

sPDL2

0.10

1 (reference)
0.66 (0.33–1.33)

1.65 (0.61–4.40)

Adjusted HR (95%CI)c
1 (reference)

1 (reference)

1 (reference)
3.36 (1.55–7.27)

sBTLA

0.14

1 (reference)
1.25 (0.62–2.54)

sLAG3

Survival
P value

1 (reference)

1 (reference)
1.75 (0.91–3.40)

sIDO

0.04

1 (reference)
0.45 (0.18–1.16)

sCTLA4

Adjusted HR (95%CI)c
1 (reference)

1 (reference)
0.62 (0.34–1.16)

sCD28

Recurrence
P value

1.57 (0.70–3.49)

0.27

1 (reference)
9.33E-04#

2.39 (0.97–5.88)

0.06

Abbreviations: OR Odds ratio, HR Hazard ratio, CI Confidence interval. Significant values in bold font
a
High- and low-level groups dichotomized by the logistic regression spline model [12]
b
Adjusted by age, gender, smoking, BMI, diabetes, and hypertension
c
Adjusted by age, gender, smoking, BMI, diabetes, hypertension, histology, grade, stage and treatment
# Significant after Bonferroni adjustment for multiple testing

sLAG3 LEVEL CORRELATES WITH REDUCED INTRA-TUMOR
CYTOLYTIC SCORE

To further validate our findings, we assessed the expression
of immune genes in ccRCC tumors from TCGA database
consisting of 533 primary ccRCC patients. We found that
the expressions of all genes were higher in tumor tissues
than corresponding normal tissues (P < 0.05) except for
CD274 (PD-L1) (Additional file 1: Figure S2).
Notably, we found that sLAG3 and sCD28 negatively
correlated with T cell cytolytic score (rho = − 0.31 and −
0.33, P = 0.05 and 0.04, respectively) in our primary
ccRCC tumors (Fig. 2b, Additional file 1: Table S6),
whereas sPDL1 positively correlated with cytolytic score
based on GZMB and PRF1 expression (Additional file 1:
Table S7). sLAG3 also negatively correlated with CD8A
expression in tumors, while sPDL1 positively correlated
with interferon gamma (IFNG) expression. We also
demonstrated that the expression of LAG3 and PDCD1
in ccRCC tumors significantly correlated with CD8A expression in both MDACC cohort and TCGA cohort
(Fig. 2c-d). The association between immune gene expression of ccRCC tumors and cancer outcomes were
also analyzed in the MDACC cohort (n = 47) and TCGA
cohort (n = 382); however, no associations were confirmed (Additional file 1: Table S8).

Discussion
In this study, we identified a panel of soluble immune
checkpoint-related proteins being associated with clinical
outcomes of ccRCC patients. We demonstrated that circulating levels of sLAG3 are associated with risk of advanced
disease; sPD-L2 level associated with risk of recurrence;
sTIM3 and sBTLA levels correlated with risk of death in
ccRCC patients. We generated a risk score combining the
two biomarkers associated with survival indicating the
soluble immune checkpoint-related proteins jointly
predict the death risk of ccRCC. Furthermore, sLAG3 and
sCD28 levels negatively correlated with the number and
cytolytic activity of T cells in ccRCC tumors. These results
highlighted the prognostic value of these soluble immune
checkpoint-related proteins and unveiled potential biological mechanisms in ccRCC development.
We identified sPD-L2 as the most significant biomarker
associated with ccRCC recurrence in this study. Previous
work has described that sPD1 enhanced anti-tumor immunity by blocking PD-L1 in tumor cells [16], whereas
sPD-L1 predicted poor prognosis in aggressive diffuse
large B-Cell lymphoma [8]. In our study, sPD-L2 but not
sPD-L1 was predictive of recurrence risk in ccRCC, and
sPD-L2 level seems to be higher than that of sPD-L1,
which is consistent with the protein expression of these
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Fig. 1 Kaplan Meier analysis of recurrence-free survival (RFS) and overall survival (OS) by levels of soluble immune checkpoint proteins in ccRCC
patients. a Survival curve of RFS according to the level of sPDL2. b-c Survival curves of OS according to the levels of sBTLA, sTIM3, respectively.
High- and low-level groups were dichotomized by the logistic regression spline model

two markers in TILs from another study [4]. This finding
is partially supported by one previous study suggesting
that high PD-L2 expression in tumor is associated with reduced cancer free survival in RCC patients [17]. The
source of sPD-L2 may be derived from tumor exosomes
[18] or alternatively activated macrophages [19] to inhibit
T cell-mediated anti-tumor response. Therefore, high
sPD-L2 could be a predictive biomarker of recurrence risk
in ccRCC patients, although the finding warrants further
confirmation in independent populations and exploration
of the underlying biological mechanisms.
High density of LAG3+ T cells is a signature of T cell exhaustion in tumors [20]. Our results indicated that high
level of sLAG3 is associated with advanced tumor stage in
ccRCC patients. This is consistent with Camisaschi’s study
that LAG3 were highly expressed in Treg cells in peripheral
blood, tumor-involved lymph nodes and within tumor tissues isolated from patents with advanced (stage III and IV)
melanoma and colorectal cancer [21]. Also, sLAG3 was also
found marginally associated with poor survival (P = 0.07),
which was supported by another study that sLAG3 was
associated with poor survival in chronic lymphocytic
leukemia, and sLAG3 could promote leukemic cell

activation and anti-apoptotic effects [22]. However, another
study of breast cancer showed that sLAG3 could serve as
“Th1” (type I T helper cell) marker and that high level of
sLAG3 predicted better OS [23]. This discrepancy may be
due to the differential regulatory role of sLAG3 in mediating
interaction between LAG3 and MHC-II, or the distinct immune landscapes of different cancer sites [20, 24]. Furthermore, we found that levels of sLAG3 negatively correlated
with CD8A (T cell marker) expression and T cell cytolytic
activity in tumors. Therefore, we propose that high level of
sLAG3 may be indicative of T cell suppression in the TME,
which in turn lead to advanced development of ccRCC.
TIM3 (HAVCR2) is an inhibitory receptor expressed
on T cell and tumor cell surfaces which regulates Th1
and cytotoxic T cell responses [25, 26]. High TIM3 and
PD1 expressions on T cells and in tumors are the signature of “deeply” exhausted status, which are frequently
observed in ccRCC [27, 28]. The soluble TIM3 is shown
to be generated by A Disintegrin and Metalloprotease
(ADAM)-mediated ectodomain shedding from both T
cells and tumor cells [29]. Our results revealed that
sTIM3 is associated with advanced disease and increased
death risk of ccRCC. This finding further confirmed
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Fig. 2 Risk score of soluble immune checkpoints as predictor of ccRCC survival and its correlation with T cell functions in primary tumors. a Risk
score derived from 2 soluble immune checkpoint proteins (sBTLA, sTIM3) predicted overall survival (OS). Risk score green line represented low-risk
group, and risk score blue dot line was medium-risk group, and red dot line was high-risk group. Risk groups were tertiled by the risk score. b
Scatter plot of sLAG3 (blue) and sCD28 (red) levels (y-axis) against CYT score (x-axis). c-d Scatter plot of LAG3 (red) and PDCD1 (blue) expression
(y-axis) against CD8A gene expression (x-axis) in ccRCC tumors from (C) MDACC cohort (n = 47) and (D) TCGA cohort (n = 533)

previous studies that TIM3 + PD1+ TILs exhibited
exhausted phenotype in the TME, thereby resulting in
poor prognosis of cancer patients [3, 30]. The mechanisms
of how sTIM3 interacts with its ligands, other inhibitory
checkpoint proteins and TCR signaling pathway in T cells
remain unclear necessitating further independent research. Interestingly, we found the association of sTIM3
with death risk was significant only in early-stage (I and
II) patients suggesting the confounding effect of staging
on survival, although our overall Cox proportional hazard
analyses have been adjusted for clinical stage. The utility
of sTIM3 as an early prognostic biomarker requires further confirmation in independent prospective studies.
BTLA is another inhibitory checkpoint protein that interacts with HVEM and LIGHT, a group of costimulatory
molecules, resulting in suppression of T cell immunity
[31]. In this study, sBTLA level (>2269 pg/mL) was identified as a predictor of poor OS in ccRCC patients indicating that sBTLA may play a similar role as membranous
BTLA in suppressing T cell response. This is in line with
Benjamin et al’ study reported that sBTLA (>1910 pg/mL)
could predict poor survival in pancreatic cancer patients
[9]. BTLA expression in gastric cancer and lymphoma is

also reported associate with poor prognosis [32, 33]. However, the immune function of sBTLA may varies by cancer
sites, which warrants further research.
CTLA4 and CD28 play opposite roles during T cell activation [34]. However, in our study sCTLA4 and sCD28
were both associated with poor outcome of ccRCC patients,
though not significant after multiple testing adjustment.
sCTLA4 has been shown as an extrinsic suppressive factor
of T cell activation, which could be prominently secreted
by T-reg cells [35]. Our results revealed that sCTLA4 is associated with increased risk of recurrence. Meanwhile,
sCD28 is also associated with death risk in our ccRCC cohort. We identified negative correlation between sCD28
and cytolytic activity in ccRCC tumors. This result is in line
with one previous study showing sCD28 with inhibitory
role in T cell proliferation in autoimmune diseases [36]. All
of the above findings suggest the potential interactions between sCD28/sCTLA4 and anti-tumor immunity mediating
their association with ccRCC outcomes.
There are several strengths to our study including the
prospective high-quality cohort with relatively long
follow-up time, the multiplex profiling of soluble immune checkpoint-related proteins and immune gene
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expressions in tumors, and the correlation analysis of
soluble immune checkpoint-related proteins and T cell
functions to provide biological validity. Despite these
strengths, we also acknowledge some limitations. First,
we have limited sample size with relatively small number
of outcome events, which might constrain the power of
our study. Limited tumor tissues available in our cohort
and partial clinical outcome information in TCGA dataset might lead to some uncertainties in our results. Additional validation within larger independent cohort is
necessary. After consideration of multiple testing, some
of the associations we identified may not be significant.
Nevertheless, the associations of sLAG3 with advanced
(stage III) disease; sPD-L2 with recurrence; sTIM3 and
sBTLA with survival remain significant after the stringent Bonferroni adjustment suggesting less likelihood
for false discovery. Second, we did not conduct mechanistic studies to determine the functional impact of soluble immune checkpoint-related proteins. Instead, we
evaluated the associations between soluble immune
checkpoint-related proteins and T cell functional gene
expressions to decipher potential mechanisms. Third,
evaluation of immune checkpoint expression in peripheral blood leukocytes may be informative to examine
any correlation between soluble protein levels and peripheral immune gene expression. Nevertheless, our
inquiry is supported by one previous study correlating
tumoral and peripheral blood T cell phenotypes with aggressiveness of ccRCC [3].

Conclusion
In this study, we identified a panel of circulating immune checkpoint-related proteins that are associated
with clinical outcomes and T cell phenotypes in ccRCC
patients. Individually and jointly, the soluble immune
checkpoint-related proteins may assist risk stratification
of ccRCC patients to identify those at high risk of recurrence or poor survival for more intensive surveillance
and/or treatment. Future study may apply these markers
to test their predictive value for treatment outcome in
immunotherapy-treated patients.
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tissue expression of immune checkpoint genes in ccRCC patients derived
from TCGA database. Maroon boxplot indicates tumor tissues (N = 533),
and green boxplot indicates normal tissues (N = 72). Wilcoxon rank sum
test was used in the comparison analysis. *indicates P < 0.05.
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